Genomics ETF


  • Genomics ETF presents exposure to emerging healthcare trends
  • The Fund provides ease of access to global leaders in Genomic Therapies, Diagnostics and e-Healthcare
  • 0.35% TER
  • Sustainable ETF with a social impact goal (SFDR Article 9)

Risks of the ETF: You may lose money up to the total loss of your investment due to the Main Risk Factors such as Industry or Sector Concentration Risk and Liquidity Risks described below, in the KID and in the sales prospectus. Evolving of the market not guaranteed.

Technology is changing the future of healthcare. Genomics and e-healthcare are shaking up antiquated health systems. VanEck’s Genomics ETF invests in the innovative companies harnessing scientific advances to develop breakthrough treatments and give patients more control over how they access care.

A Huge Prize for a Genomics ETF

The size of the healthcare market is gigantic. In America alone, it consumes 18% of GDP, equivalent to $3.6trn a year.1 In other wealthy countries, the share is lower, around 10%, but it is increasing as populations age. Just as science is developing new gene therapies, so too the pandemic has made people comfortable with digitally-mediated care. That means healthcare is ripe for disruption.

1 How health care is turning into a consumer product. The Economist. 15 Jan 2022.

Genomics ETF Provides Access to Disruptive Innovators

Through tracking the companies driving healthcare’s future, our Genomics ETF aims to generate returns for investors. Such is the nature of healthcare’s modernization that it also brings clear social benefits through improved medical care and wider access to treatments.

Gene therapies focus on modifying cells to treat serious diseases. They target the fundamental causes of disease, potentially enabling cures for rare and inherited diseases. They may also have applications for more common conditions. New clinical data is expanding genetic therapy pipelines.

VanEck Genomics and Healthcare Innovators UCITS ETF


  • Our Genomics ETF presents access to leading genomics and e-healthcare companies in a single trade
  • Be an early investor in healthcare’s tech disruption
  • The Fund allows to profit from the move to proactive, predictive and personalized medicine
  • Invest in a modernization with clear social benefits
  • It is diversified across at least 25 companies

Risk indication: 7 out of 7

Lower risk: Typically lower reward

Higher risk: Typically higher reward

Main Risk Factors of a Genomics ETF


This risk exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. This is a factor to consider before investing in a Genomics ETF. 

For more information on risks, please see the “Risk Factors” section of the relevant Fund’s prospectus, available on

Discover more ETFs

More ETFs

Why Invest in VanEck ETFs?

  • Since we were founded in 1955 we have constantly been at the forefront of innovation, giving you access to new opportunities like gold funds, emerging market funds and ETFs.
  • We are privately-held, allowing us to focus on our clients’ long-term interests.
  • Our ETFs are transparent: they acquire the underlying securities (no synthetic replication). Securities are not lent out.*
* This only holds for VanEck’s European ETFs.